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ABSTRACT
Objective: We aimed to assess adherence to the Australian national guideline (COPD-X) against audited
practice, and to document the outcomes of patients hospitalised with an acute exacerbation of chronic
obstructive pulmonary disease (COPD) at discharge and 28 days after.
Methods: A prospective clinical audit of COPD hospital admission from five tertiary care hospitals in five
states of Australia was conducted. Post-discharge follow-up was conducted via telephone to assess for
readmission and health status.
Results: There were 207 admissions for acute exacerbation (171 patients; mean 70.2 years old; 50.3%
males). Readmission rates at 28 days were 25.4%, with one (0.6%) death during admission and eight
(6.1%) post-discharge within 28 days. Concordance to the COPD-X guidance was variable; 22.7%
performed spirometry, 81.1% had blood gases collected when forced expiratory volume in 1 s was <1 L,
99.5% had chest radiography performed, 95.1% were prescribed systemic corticosteroids and 95% were
prescribed antibiotic therapy. There were 89.1% given oxygen therapy and 92.6% when arterial oxygen
tension was <80 mmHg; 65.6% were given ventilatory assistance when pH was <7.35. Only 32.4% were
referred to pulmonary rehabilitation but 76.8% had general practitioner follow-up arranged.
Conclusion: When compared against clinical practice guidelines, we found important gaps in management
of patients admitted with COPD throughout tertiary care centres in Australia. Strategies to improve
guideline uptake are needed to optimise care.
@ERSpublications
A multisite audit of hospital admissions for patients experiencing #AECOPD in Australia
highlighted important gaps in management when compared against national guidelines. Further
focus on how we can improve guideline uptake by clinicians is needed. http://bit.ly/2VjGnHw
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Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous disease that is responsible
for a major burden of illness. In Australia, 7.5% of people ⩾40 years old have COPD of Global Initiative
for Obstructive Lung Disease (GOLD) stage II or above, increasing to nearly 30% in the >75-years age
group [1]. COPD is the fifth leading cause of death in Australia [2] and World Health Organisation
estimates predict that COPD will become the third leading cause of death worldwide by 2030 [3].
Acute exacerbations of COPD (AECOPD) are common occurrences, characterised by a deterioration of
respiratory symptoms that necessitates additional therapy [4]. This deterioration affects patients’ health
status, and contributes to disease progression, increased rates of hospitalisation and death [4]. AECOPD
make up the highest share of the total COPD economic burden [4], expending significant healthcare
resources [5]. COPD is the leading cause of avoidable hospital admissions amongst chronic disease in
Australia, with >78000 potentially preventable admissions in 2016–2017 [6]. Additionally, Australia has
one of the highest rates of hospital admissions for COPD within the Organisation for Economic
Co-operation and Development [7]. These data highlight the importance of using the latest evidence to
minimise AECOPD, reduce future risks and prevent hospitalisation.
Guidelines facilitate the incorporation of research evidence into clinical practice and support clinicians in
their patient care decisions [8]. The Australian and New Zealand COPD-X guidelines seek to facilitate
changes in clinical practice based on sound evidence [9]. However, guideline utilisation in clinical practice
can be challenging and uptake remains poor [8], with previous national audits of practice [10, 11] and
international audits [12–14] demonstrating variable adherence to evidence-based guidelines in the
management of AECOPD.
The aims of this study were to collect prospective data on the management of hospital admissions for
AECOPD across multiple sites in Australia and to compare contemporary management against a best
practice guideline (COPD-X) [9]. We hypothesised that there would be discordance in the adherence to
these guidelines and that the level of adherence would be similar across tertiary care sites.
Methods
A prospective clinical audit of AECOPD hospital admissions was conducted in tertiary care hospitals in
five of the eight states/territories of Australia: Flinders Medical Centre (South Australia), John Hunter
Hospital (New South Wales), Northern Health (Victoria), Royal Hobart Hospital (Tasmania) and The
Prince Charles Hospital (Queensland). At 28 days post-discharge, participants were followed-up by
telephone to determine readmission events and health status.
Institutional ethics approval was gained for all sites participating in the study (lead site Hunter New
England Human Research Ethics Committee reference number 12/10/17/5.05) and all participants
provided written informed consent.
Audit tool
To reflect the Australian context, a previously validated clinical audit tool was modified from the UK
COPD tool [10, 15]. Core data collected included patient characteristics, comorbidities, patient
accommodation, vital signs, chest radiographic appearance, pharmacological interventions, respiratory
status or support required, and spirometry results. Health status was assessed using the COPD Assessment
Test (CAT) [16], measured during admission and at 28 days post-discharge by telephone follow-up. Data
were collected between October 2012 and April 2013, and were entered into a purpose-built, web-based
database. Data were assessed against the COPD-X guidelines to determine concordance. These guidelines
have been available to clinicians for use since 2003 [17] and are updated quarterly; variables that we
measured concordance against had not undergone any recommendation changes in the preceding
12 months. For the purpose of this audit, version 2.34 (November 2012) was utilised [9].
Participants
Each centre prospectively identified admissions with AECOPD to their healthcare facility, using methods
most appropriate to the individual site. Patients admitted with an AECOPD were approached and invited
to participate. Inclusion and exclusion criteria are presented in table 1.
Data analysis
Analyses were performed using Stata 14 (Stata Corporation, College Station, TX, USA). Categorical data
were described using frequencies and percentages. Continuous data were described using means and
standard deviations for normally distributed data, and medians and interquartile ranges (IQRs) for
non-normally distributed data. Associations between categorical variables were investigated using
Chi-squared and Fisher’s exact tests, with continuous data compared using Student’s t-test or Wilcoxon
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signed rank. Comparison between the treatment sites were investigated with ANOVA for normally
distributed data, with Bonferroni-corrected post hoc comparisons conducted when required.
Kruskal–Wallis was used for non-normally distributed data. The relationship between selected variables
and readmission were investigated using logistic regression, and length of stay via negative binomal
regression and linear regression as appropriate. p-values of <0.05 were considered significant.
Venous blood gas results were transformed by adding 0.03 to the venous pH result as summarised in the
review by BYRNE et al. [18].
Results
Demographic characteristics of patient population
Data were collected for 207 admissions in 171 patients with AECOPD. Table 2 presents demographic data,
select clinical parameters and admission outcomes for each of the study sites. Most patients had a
diagnosis of COPD prior to their admission. The mean±SD age of patients was 70.2±9.9 years and 50.3%
were male. Most were former smokers, with current smokers representing approximately one third. Over
half lived with another person. Patients had a mean±SD of 3.7±2.0 comorbidities. Patient characteristics
were generally similar across sites.
Almost all patients reported an increased level of breathlessness and around half reported a change in
sputum colour prior to admission. Nearly three quarters had been hospitalised for COPD within the
previous 24 months. There was one death during hospitalisation and eight (6.1%) within 28 days following
discharge. The median length of stay (LOS) was 6 days (IQR 3–9 days), with significant differences seen in
the LOS between sites 1 and 2 (p<0.001) and sites 1 and 4 (p<0.001).
Readmissions within 28 days occurred in 36 patients (25.4%) and these patients had more comorbidities
(4.6±2.2 versus 3.5±1.8, p=0.002). CAT score was not found to predict death or readmission. In this
cohort, it was associated with LOS. For each unit increase in CAT score at discharge, there was an increase
of 0.17 days in LOS (p=0.044; 95% CI 0.004–0.343). At 28 days, the CAT score was significantly better
than at discharge (21.6±7.9 versus 24.5±6.9, p<0.001); however, the discharge score did not differ
significantly between those who were and were not readmitted within 28 days (mean 26.4±7.0 versus
24.0±6.3, p=0.79).
A quarter of patients were discharged home on oxygen, with significant differences observed between sites
(p=0.016). Of these, seven (19.4%) out of 36 patients had been prescribed domiciliary oxygen for the first time
during the audited admission, with differences seen between the sites (p=0.037); most (28 out of 35, 80%) were
prescribed oxygen via a concentrator (p=0.129) and over a quarter of patients discharged on oxygen (nine out
of 34, 26.5%; p=0.018) received follow up in an oxygen clinic. However, of those who did not have follow up in
an oxygen clinic, 83.3% (25 out of 30, p=0.033) had follow up with a respiratory physician. In many cases, if
not all, this review would have included an assessment of long-term oxygen therapy requirements.
Concordance to COPD-X guidelines
Table 3 outlines the COPD-X management recommendations, and summarises the overall and site-specific
concordance against a selection of these recommendations.
Spirometry was performed in only 22.7% of admissions. There were significant differences (p<0.001) and
wide variation between sites (range 1.5%–53.2%). Of the patients who had forced expiratory volume in 1 s
(FEV1) documented, 106 had an FEV1 <1.0 L, with 81.1% of these having an arterial blood gas (ABG) or
venous blood gas (VBG) collected (p=0.017). Overall, 156 patients (75.4%) had either an ABG or a VBG
taken at some point during their admission. There was a high level of concordance with chest radiography,
performed in 99.5% within the first 24 h (p=0.039).
TABLE 1 Inclusion and exclusion criteria
Inclusion criteria Diagnosis of COPD: smoking history >10 pack-years, post-bronchodilator
FEV1/FVC <0.7 and FEV1 <80% predicted (post-bronchodilator)
Increased symptoms: cough, sputum volume or purulence, breathlessness
Age >35 years
Exclusion criteria New chest radiographic infiltrate consistent with pneumonia
Other causes of breathlessness; heart failure, pulmonary embolism, etc.
Asthma
Inability to provide informed consent
FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity.
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The prescription of systemic corticosteroids was high (range 90–100%, p=0.085). Antibiotic prescription
for those with a documented change in sputum colour was also high overall (95.0%), although lower at
site 2 compared to other sites (66.7%, p=0.085). However, most patients with no change in the colour
(85.7%) or volume (84.9%) of their sputum were also prescribed antibiotics.
Pulse oximetry data were not recorded during this audit, so appropriate use of oxygen could not be
determined. However, oxygen was administered to 89.1% of patients, with only 27% of these having a
written oxygen prescription (range 3.2–76.9%, p<0.001). Overall, 32 patients had a pH <7.35, with
ventilatory assistance used in 21 (65.6%). Of the 18 patients who had the type of ventilatory assistance
documented, it is clear that three received invasive ventilation. Reasons for not using noninvasive ventilation
(NIV) or invasive ventilation included a documented decision not to escalate to NIV or invasive ventilation
(18.2%), “patient responded to medical therapy” (45.6%) and in 36.4%, no reason was listed.
TABLE 2 Patient characteristics and key clinical indicators
All Sites Site 1 Site 2 Site 3 Site 4 Site 5 p-value
Patients n 171 46 8 37 50 30
Male sex 86/171 (50.3%) 24/46 (52.2%) 5/8 (62.5%) 18/37 (48.7%) 22/50 (44.0%) 17/30 (56.7%) 0.761
Age years mean±SD 70.2±9.9 69.6±9.5 71.8±8.7 69.9±11.2 70.5±9.6 70.6±10.4 0.976
Previous diagnosis COPD 162/166 (97.6%) 44/45 (97.8%) 8/8 (100%) 35/36 (97.2%) 46/48 (95.8%) 29/29 (100%) 0.926
Caucasian 163/169 (96.5%) 44/46 (95.7%) 8/8 (100%) 37/37 (100%) 46/48 (95.8%) 28/30 (93.3%) 0.650
Smoking status
Current 59/161 (36.7%) 18/44 (40.9%) 5/8 (62.5%) 11/35 (31.4%) 16/44 (36.4%) 9/30 (30%) 0.515ƒƒ
Former 99/161 (61.5%) 26/44 (59.1%) 3/8 (37.5%) 24/35 (68.6%) 26/44 (59.1%) 20/30 (66.7%)
Never 3/161 (1.9%) 0/44 (0%) 0/8 (0%) 0/35 (0%) 2/44 (4.6%) 1/30 (3.3%)
Living arrangements
Residential care 9/169 (5.3%) 1/46 (2.2%) 1/8 (12.5%) 2/35 (5.7%) 3/50 (6%) 2/30 (6.7%) 0.251ƒƒ
Alone 65/169 (38.5%) 19/46 (41.3%) 5/8 (62.5%) 8/35 (22.9%) 20/50 (40%) 13/30 (43.3%)
With someone 95/169 (56.2%) 26/46 (56.5%) 2/8 (25%) 25/35 (71.4%) 27/50 (54%) 15/30 (50%)
Comorbidities mean±SD 3.7±2.0 3.7±1.8 2±1.4+ 4.6±2.2+,§ 3.4±1.8§ 3.5±2.0 <0.05
Hypertension 83/171 (48.5%) 18/46 (39.1%) 2/8 (25%) 16/37 (43.2%) 28/50 (56%) 19/30 (63.3%) 0.109
Gastrointestinal
disease
64/171 (37.4%) 26/46 (56.5%) 2/8 (25%) 5/37 (13.5%) 18/50 (36%) 13/30 (43.3%) 0.002
Ischaemic heart
disease
49/170 (28.8%) 14/46 (30.4%) 1/8 (12.5%) 10/37 (27%) 12/49 (24.5%) 12/30 (40%) 0.489
Increasing
breathlessness#
165/169 (97.6%) 46/46 (100%) 8/8 (100%) 35/36 (97.2%) 49/50 (98%) 27/29 (93.1%) 0.402
Change in sputum
colour#




169 (24, 20–32) 45 (26, 22–32)ƒ 7 (20, 19–25) 37 (24, 23–30) 50 (26, 20–36) 30 (22, 20–26)ƒ 0.013
Previous admission for
COPD¶
109/148 (73.7%) 25/40 (62.5%) 4/4 (100%) 22/28 (78.6%) 35/48 (72.9%) 23/28 (82.1%) 0.314
Length of stay days
median (IQR)
6 (3–9) 4 (2–6)##,¶¶ 12 (7–18)## 6 (4–10) 6.5 (4–9)¶¶ 6 (3–12) <0.001
COPD score at discharge
n (mean±SD)
158 (24.6±6.9) 36 (24.0±6.1) 7 (26.0±5.3) 37 (22.9±7.8) 48 (26.7±6.6) 30 (23.6±6.7) 0.100
COPD score on follow-up
post-discharge n
(mean±SD)
126 (21.6±7.9) 32 (24.4±7.0)++ 4 (27.5±5.4) 27 (19.9±5.4) 38 (22.9±8.6)§§ 25 (16.8±7.1)++,§§ 0.001
Discharged home on
oxygen
41/158 (26.0%) 12/46 (26.1%) 5/7 (71.4%) 5/28 (17.9%) 8/47 (17.0%) 11/30 (36.7%) 0.016
Readmission within
28 days
36/142 (25.4%) 12/45 (26.7%) 2/5 (40%) 7/20 (35.0%) 8/42 (19.1%) 7/30 (23.3%) 0.638
Death during admission 1/169 (0.6%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 1/30 (3.3%) 0.219
Death after discharge 8/132 (6.1%) 2/43 (4.7%) 0/0 (%) 2/21 (9.5%) 2/42 (4.8%) 2/24 (8.3%) 0.781
Data are presented as n/N (%), where N is the number of data available for analysis and % are is documented values (unrecorded, unknown
and undocumented values have been treated as missing values), unless otherwise stated. Data are calculated on 171 patients. IQR:
interquartile range. #: prior to admission; ¶: in previous 24 months. +: significant difference between sites 2 and 3 (p=0.006); §: significant
difference between sites 3 and 4 (p=0.043); ƒ: significant difference between sites 1 and 5 (p=0.013); ##: significant difference between sites 1
and 2 (p⩽0.001); ¶¶: significant difference between sites 1 and 4 (p⩽0.001); ++: significant difference between sites 1 and 5 (p=0.002);
§§: significant difference between sites 4 and 5 (p=0.020); ƒƒ: overall p-value.
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TABLE 3 Observed frequencies for each admission for management of acute exacerbation of COPD according to COPD-X
guideline recommendations
Category COPD-X guideline recommendation
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Data calculated on individual admissions (n=207); % are for documented values (unrecorded, unknown and undocumented values have been
treated as missing values). FEV1: forced expiratory volume in 1 s; ABG: arterial blood gas; VBG: venous blood gas; PaO2: arterial oxygen
tension; GP: general practitioner.
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Overall, 76.8% of patients had general practitioner follow-up arranged prior to discharge; however, there
was wide variation between sites (range 16.7–100%, p<0.001). Referral to pulmonary rehabilitation was low
in most centres (mean 32.4%, range 10.3–71.7%; p<0.001).
We examined the impact of concordance on LOS and readmission for recommendations where there was
<75% concordance in the COPD-X categories “confirming exacerbation/categorising severity”
(performance of FEV1) and “optimising treatment” (receiving ventilatory assistance). Neither performance
of FEV1 (incident rate ratio (IRR) 1.36, p=0.185; 95% CI 0.862–2.156) or receiving ventilatory assistance
(IRR 1.196, p=0.217; 95% CI 0.900–1.589) were significantly associated with LOS. In addition, there was
no statistically significant difference (p=0.090) between patients who did or did not receive ventilatory
support on readmission to hospital. However, patients who did not perform spirometry as part of the
audited admission were 3.6 times more likely to be readmitted (p=0.007, 95% CI 1.413–9.173); 14.3% of
those who performed a spirometry were readmitted, compared to 37% of those who did not perform a
spirometry during their admission.
Discussion
This prospective study of five tertiary care facilities across Australia demonstrated that there are variations
in concordance to the COPD-X guideline for inpatient management of patients with AECOPD.
Interventions with high concordance included performance of chest radiography, provision of treatment
with oral corticosteroids and antibiotics, and administration of oxygen therapy. Discordance was seen to
the recommendations of performing spirometry and referral to pulmonary rehabilitation, with rates
varying substantially across sites. This study reflects actual clinical practice and has provided insight into
the gaps in AECOPD management when compared to evidenced-based guidelines.
Patient characteristics were similar to those of other audits [10, 11, 19]. The median LOS in this group was
6 days. Our data are similar to previous Australian studies [10, 11] that reported a median LOS of 5 days,
but shorter than international data where median LOS has been reported between 7 and 8 days [20–22].
The reason for the significant difference seen in LOS between Australian sites is not clear but may be
related to variations in management or local protocols. CAT score was shown to impact LOS,
demonstrating its value as a reportable patient outcome for use during hospital admission.
Smoking rates, while similar to other Australian data [10, 11], were higher than those reported by
European studies [21, 22] (9% and 30%, respectively). Smoking rates in the Australian cohort are high
when compared to the national average (9.3%) in the 65–75-year age group [23], highlighting the need for
effective smoking cessation strategies for patients with COPD.
Our data support previous national [10, 19] and international [24] findings demonstrating underutilisation of
spirometry. These results compare to previous national audits. A study by KHIALANI et al. [19] reported a
measured FEV1 in 17.2% of patients, while PRETTO et al. [10] reported spirometry being recorded in 29%.
COPD-X suggest that spirometry during admission is of value in assessing severity of an AECOPD [9], and
may be useful in confirming diagnosis and assessing severity and clinically useful for ongoing management [25].
In our audit, not having spirometry performed during the admission increased the odds of 28-day readmission.
Several studies have demonstrated that valid and reproducible spirometry traces can be obtained in
patients admitted with AECOPD, and is important in confirming the presence of airflow limitation where
diagnosis of COPD is not confirmed [26, 27]. Poor spirometry uptake may be due to differences in
recommendations by key guidelines on the need for spirometry testing during admission [4, 28]. While
COPD-X argues that “even the sickest of patients can perform an FEV1 manoeuvre” [28], the GOLD
guidelines [4] do not routinely recommend that sick patients perform spirometry. It is also important to
consider the practicality or capacity of emergency department staff to obtain acceptable spirometry traces.
Patient admissions are not restricted to “office hours” when lung function laboratories are open. In
addition, appropriate equipment and staff who are skilled in obtaining accurate measurements may not
always be available at the times when patients present to the emergency department. However, acute care
services need to be improving diagnostic accuracy in the assessment of COPD severity and demonstrating
the importance of this diagnostic tool to primary care practitioners. Any admission to acute care services
can present an opportunity for reassessment and classification of the severity of airflow limitation to guide
decisions on appropriate treatment, particularly as poor use of spirometry in primary care has been shown
to be associated with under and overdiagnosis of COPD patients [29].
COPD-X [9] recommend measurement of ABGs if the FEV1 is <1.0 L or 40% predicted, or when oxygen
saturations are <90%. Our study did not record peripheral oxygen saturation data and rates of spirometry
on admission were low; however, while three quarters of all patients had either an ABG or VBG collected
(156 patients, 75.3%), 18.9% of admissions who had a FEV1 <1.0 L did not have blood gases taken. The
reason(s) not to perform these measurements are unknown and our study was not designed to identify
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these, but these data highlights gaps in management. Early identification of hypercapnic respiratory failure
is important, to identify both those at highest risk of death during admission and those who will benefit
from treatment with NIV [5]. Failure to obtain blood gas measurements may lead to missed opportunities
to provide NIV to those in acute respiratory failure. Blood gas collection occurred in 81.1% for those with
a FEV1 <1.0 L and in 75.3% of patients overall. Results compared to other Australian studies where
collection rates (ABG or VBG) ranged between 62% and 77% [10, 19, 30, 31]. They also compare
favourably to international literature from South East Asia, where rates of blood gas collection occurred in
less than a quarter of patients admitted to the emergency department [31]. However, blood gas collection
is consistently higher in Europe, with documented rates between 80% and 90% [13, 21, 22].
NIV was indicated in 32 patients, with 21 receiving ventilatory assistance. National [10, 19, 31] and
international [13, 31] data highlight missed opportunities for the use of NIV in patients with acidosis.
This equates to 11 (34%) patients who could have potentially benefited from this therapy. High-quality
evidence now exists to support the use of NIV in addition to usual care for patients with acute
hypercapnic respiratory failure; interestingly, the number needed to avoid one death is 12, very close to the
number in our audit missing out on treatment [32]. NIV has been shown to reduce mortality by up to
46%, reduce the need for intubation by 65% and, on average, reduces the LOS for these patients by
3.5 days [32]. Our results confirm that NIV is underutilised.
Excellent concordance was seen for the recommendation to perform a chest radiograph, with almost 100%
adherence seen in our study. Both national [10, 19, 30, 31] and international [13, 21, 31] data consistently
demonstrate high concordance (>90% across studies) with this recommendation. Our study also
demonstrates high concordance across all sites (range 90–100%) for corticosteroid prescription. These
results are higher than those reported by PRETTO et al. [10]. It also compares favourably to international
data that demonstrate concordance rates between 82.3% [13] and 92% [21].
In most admissions (95.0%) audited, patients were prescribed antibiotics when there was evidence of
change in sputum colour. These compare favourably to the study by PRETTO et al. [10] but lower
prescription rates were noted in studies that have examined Australian emergency department
management of patients with AECOPD, where rates ranged between 58% and 75% [19, 30, 31]. Guidelines
[9] recommend antibiotic cover for patients with purulent sputum. This audit did not specifically
investigate presence of purulent sputum; however, it did ask if a change in sputum colour was noted. Our
study also demonstrated high rates of antibiotic prescription in patients who had no documented change
in sputum colour (85.7%). This indicates a potential overprescription of antibiotics in this group. TANG
et al. [11] identified that 45% of patients were overprescribed antibiotic therapy. A number of studies have
identified inappropriate prescription of antibiotic therapy in the AECOPD patient cohort [12, 33, 34].
Furthermore, a 2018 Cochrane review concluded that aside from AECOPD patients who are treated in an
intensive care unit, the effects of antibiotic therapy use in this patient group is small [35]. Antibiotic
resistance is a major public health problem [36], one contributing factor associated with the emergence of
multidrug-resistant bacteria is inappropriate prescription of antibiotics [37]. Our data demonstrates that
improvement is needed to ensure antibiotics are prescribed in those who would most benefit.
Rates of oxygen use during an acute exacerbation are high in both national [10, 11] and international [13,
21] literature within the COPD cohort, with its use recommended for those who are hypoxic. Similarly,
oxygen use across all sites was high in our audit. It was difficult to assess the appropriateness of delivery in
the absence of more specific clinical data. The written prescription of oxygen differed significantly between
sites, with rates of prescription poor (3.2%) at two sites while significantly better rates observed at another
(76.9%). Reasons for these differences in prescription rates are not clear from the data collected. The
practice of prescribing oxygen therapy is poor internationally, with many reasons offered in the literature
and multiple interventions trialled in efforts to improve this practice [38]. However, quality improvement
projects in the UK have demonstrated improvements in the practice of oxygen prescription, the 2017–2018
audit demonstrating that 72% of admissions requiring oxygen having a prescription [39]. Notably, the
Thoracic Society of Australia and New Zealand (TSANZ) did not release their clinical practice guidelines
on oxygen use in adults until 2015, which was after the current audit was undertaken (2012–2013).
However, the British Thoracic Society guidance [40] advocating for oxygen prescription has been
published since 2008.
Less than a third of patients were referred to pulmonary rehabilitation. While this result is not unexpected
or particularly poor, when comparing this to current guidance that asks clinicians to “consider pulmonary
rehabilitation at any time following an exacerbation” [41], a rate of 32% certainly demonstrates room for
improvement given the evidence that supports the efficacy of this intervention [42, 43]. Considering the
metropolitan location of all study sites, one could reasonably expect to find the largest number of and
easiest access to pulmonary rehabilitation programmes. The low referral rates demonstrate that there is
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scope to improve referral to pulmonary rehabilitation. Both national [10, 11] and international [24] data
have consistently demonstrated low rates of referral to pulmonary rehabilitation programmes despite
high-quality evidence demonstrating it improves quality of life, exercise capacity and reduces healthcare
utilisation [42]. The TSANZ pulmonary rehabilitation guideline recommends provision of pulmonary
rehabilitation within 2 weeks of discharge and efforts to improve referral are needed [43]. General
practitioner follow-up was high overall (76.8%); however, significant differences were seen in referral rates
between sites (range 16.7%–100%).
This study presented several strengths and limitations. To our knowledge, this is the first national audit
conducted in multiple sites across five Australian states. This provides a representative sample from an
Australia tertiary care perspective. The eligibility criteria were broad and inclusive, in order to reflect
clinical practice. The prospective study design avoided the inclusion of patients whose diagnostic codes
were incorrect, as only patients who had been assessed by a clinician as having an AECOPD were
included. This design, however, also presents some limitations. While patients were identified
prospectively, data were recorded from medical records, which led to some missing and/or inconsistently
coded variables. Poor documentation of patient data in the patient notes may have led to perceived poor
concordance even where none may have existed in practice. In addition, this was a real-world clinical audit
conducted as part of usual clinical care. The real-world nature of this study meant that there were
differences in the levels of data acquisition between sites.
Overall, important gaps in management were seen nationally when compared against the COPD-X
guideline. There is scope for improvements in performance of FEV1 and referral to pulmonary
rehabilitation programmes. In addition, increased utilisation of NIV may reduce mortality and
endotracheal intubation. Strategies that have demonstrated improvements in the quality of care for
AECOPD have been highlighted in the literature and deserve serious consideration for inclusion within
the Australian context. In the UK, continuous clinical audit was commenced in 2017 for COPD care. This
strategy has seen real improvements in the quality of care received by patients admitted with AECOPD
[39]. In addition, strategies such as the use of care bundles have been shown to decrease readmission rates
in the AECOPD patient group [44]. Further exploration around the feasibility of such strategies is needed
in Australia to improve best evidence uptake, clinical practice and patient outcomes.
Conclusion
This study found important gaps in the management of patients admitted with COPD throughout tertiary
care centres in Australia and variation in concordance with clinical practice guidelines between centres.
Further focus on how we can improve the uptake of guidelines by clinicians is needed.
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